A randomized surgical window-of-opportunity trial reported in Nature Communications shows that giving dual immune checkpoint blockade before surgery substantially boosts T-cell infiltration and correlates with longer survival in recurrent glioblastoma. The approach emphasizes perioperative immune priming, aiming to convert the surgical setting into an immunologically informative moment. Separately, a technical case report describes an integrated drug-device platform enabling safe intraoperative photodynamic therapy for glioblastoma after fluorescence-guided resection. While limited to a single patient, it supports feasibility for combining real-time imaging with therapeutic delivery in the operating room. Together, the reports highlight two different execution paths to amplify glioblastoma immune effects—systemic checkpoint timing around resection and device-guided intraoperative treatment—both relevant to how trials are being designed for hard-to-treat brain tumors.
Get the Daily Brief